• 30 ΝΟΈ 15
    • 0
    Η προθεραπεία με ομαλιζουμάμπη βοηθάει στην πρόληψη κρίσεων άσθματος σε παιδιά

    Η προθεραπεία με ομαλιζουμάμπη βοηθάει στην πρόληψη κρίσεων άσθματος σε παιδιά

    A study shows that omalizumab (Xolair®, Genentech, Novartis) used in combination with standard care four to six weeks before the start of the school year helps to prevent asthma exacerbations in inner-city children and teenagers come fall. The paper reporting the clinical trial’s results is titled “Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations” and was published in The Journal of Allergy and Clinical Immunology.

    Based on previous clinical trials, researchers hypothesized that a short-term targeted therapy can potentially prevent asthma exacerbations at the same time as exposure to the treatment is reduced. Xolair was approved by the U.S. Food and Drug Administration (FDA) in 2003 for the treatment of allergic asthma patients with moderate to severe asthma whose symptoms are not fully managed by inhaled corticosteroid therapy.

    Genentech’s three-arm multicenter clinical trial, called “Preventative Omalizumab or Step-up Therapy for Fall Exacerbations (PROSE),” aimed to compare omalizumab to placebo and omalizumab to inhaled corticosteroid (ICS). The study enrolled 478 children, ages 6 to 17, with recent asthma exacerbations and from inner-city neighborhoods. They were randomly divided into treatment with omalizumab, placebo, or an inhaled corticosteroid boost.

    Mid-summer Asthma Treatment May Help Prevent Fall Flare-ups.

    Study finds short-term therapy with omalizumab effective in school-age children

    Results show that the exacerbation rate come the start of school in the fall was significantly lower in the omalizumab group compared to the placebo group, with an incidence of 11.3% and 21% respectively. No significant difference was observed between omalizumab and the ICS group. In a prespecified subgroup analysis, among participants with an exacerbation during the run-in phase of the trial, omalizumab was more effective than placebo (6.4% vs. 36.3%) and the inhaled corticosteroid therapy (2% vs 27.8%). Furthermore, omalizumab provoked an INF- α increase, a response associated with immunosuppression, and in the omalizumab group, this improvement correlated positively with fewer exacerbations. Researchers registered rare and similar adverse effects across the study groups.

    Researchers concluded that, “adding omalizumab before return to school to ongoing guidelines-based care among inner-city youth reduces fall asthma exacerbations, particularly among those with a recent exacerbation. Our study shows that an effective, preventative strategy for fall exacerbations can be achieved with targeted, seasonal treatment using omalizumab, suggesting a paradigm shift for managing high-risk patients,” Dr. Stephen J. Teach, of Children’s National Health System in Washington, D.C., said in a press release.

    Leave a reply →

Ωράριο λειτουργίας

Ιατρείο Κηφισιάς

Αιμοδιάγνωση MED, 210-8075448
Χαριλάου Τρικούπη 197 Κηφισιά 14564

Τρίτη 13:00 με 16:00

Ιατρείο Αθήνας

Doctor's Hospital, 210-8807000
Κεφαλληνίας 26, Αθήνα 11257

Πέμπτη 13:00 με 16:00

Ιατρείο Γλυφάδας

Mediterraneo Hospital, 210-9117000
Ηλείας 8, Γλυφάδα 16675

Κατόπιν ραντεβού

Ιατρείο Αμαρουσίου

210-6100880
Αλαμάνας 3, 15125, Μαρούσι

Καθημερινώς 16:00 με 21:00 εκτός Πέμπτης
Όπισθεν Ιατρικού Κέντρου, στη διασταύρωση της Αττικής Οδού (έξοδος 11) με τη Λ. Κηφισίας

Ιατρείο Αμπελοκήπων

Βιοκλινική Αθηνών, 210-6962600
Γερουλάνου 15, Αθήνα 11524

Πέμπτη 16:00 με 18:00
Πλησίον εξόδου metro Πανόρμου

Πρωινά και Σάββατο πρωί δεχόμαστε επισκέψεις στο Ιατρείο Αμαρουσίου κατόπιν ραντεβού.

Για επείγοντα περιστατικά καλέστε: 6979683589

  • Τηλέφωνο: 210 6100880

  • Κινητό: 6979 683589

  • E-mail: info -at- athensallergy -dot- gr

Αλλαγή μεγέθους γραμματοσειράς
Αλλαγή Χρώματος